Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: Dissociation between anticoagulant and antithrombotic effect of heparin

Blood

Volumn 104, Issue 10, 2004, Pages 3173-3180

  Eslin, Don E ^b   Zhang, Chunyan ^b   Samuels, Kathleen J ^b   Rauova, Lubica ^b   Zhai, Li ^b   Niewiarowski, Stefan ^b   Cines, Douglas B ^b   Poncz, Mortimer ^b   Kowalska, M Anna ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOCYTE FACTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; TRANSGENIC MOUSE;

EID: 3843072270     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3994     Document Type: Article

References (58)

1. Holt JC, Niewiarowski S. Biochemistry of alpha granule proteins. Semin Hematol. 1985;22:151-163.
2. Fukami MH, Holmsen H, Kowalska MA, Niewiarowski S. Platelet secretion. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2001:561-573.
3. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med. 1999;50:425-440.
4. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197:1537-1549.
5. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem. 1976;251:4273-4282.
6. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem. 1997;272:20508-20514.
7. Stuckey JA, St Charles R, Edwards BF. A model of the platelet factor 4 complex with heparin. Proteins. 1992;14:277-287.
8. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant human platelet factor 4. Biochemistry. 1994;33:8361-8366.
9. Rybak ME, Gimbrone MA Jr, Davies PF, Handin RI. Interaction of platelet factor four with cultured vascular endothelial cells. Blood. 1989;73:1534-1539.
10. Capitanio AM, Niewiarowski S, Rucinski B, et al. Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta. 1985;839:161-173.
11. Rucinski B, Stewart GJ, De Feo PA, Boden G, Niewiarowski S. Uptake and processing of human platelet factor 4 by hepatocytes. Proc Soc Exp Biol Med. 1987;186:361-367.
12. Han ZC, Zhang XJ, Xi XD, et al. [Platelet factor 4 acts as both inhibitor and protector of hematopoietic precursor cells: possibie mechanism of action]. Shi Yan Sheng Wu Xue Bao. 1995;28:415-426.
13. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood. 1995;86:2559-2567.
14. Gengrinovitch S, Greenberg SM, Cohen T, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem. 1995;270:15059-15065.
15. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990;82:848-853.
16. Yoshimitsu K, Wright KC, Wallace S, Charnsangavej C, Mavligit GM. Hepatic arterial infusion of recombinant platelet factor-4 suppresses metastases to the lungs from tumors implanted into the livers of rabbits. Cancer. 1995;75:2435-2441.
17. Bebawy ST, Gorka J, Hyers TM, Webster RO. In vitro effects of platelet factor 4 on normal human neutrophil functions. J Leukoc Biol. 1986;39:423-434.
18. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000;67:471-478.
19. Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A. 1981;78:4584-4587.
20. Stoeckle MY, Barker KA. Two burgeoning families of platelet factor 4-related proteins: mediators of the inflammatory response. New Biol. 1990;2:313-323.
21. Harker LA, Hanson SR. Platelet factors predisposing to arterial thrombosis. Baillieres Clin Haematol. 1994;7:499-522.
22. Okuno T, Crockatt D. Platelet factor 4 activity and thromboembolic episodes. Am J Clin Pathol. 1977;67:351-355.
23. Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 1979;53:604-618.
24. Niewiarowski S. Report of the working party on platelets. Platelet factor 4 (PF4), platelet protein with heparin neutralizing activity. Thromb Haemost. 1976;36:273-276.
25. Scully MF, Weerasinghe K, Kakkar VV. Inhibition of contact activation by platelet factor 4. Thromb Res. 1980;20:461-466.
26. Dumenco LL, Everson B, Culp LA, Ratnoff OD. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med. 1988;112:394-400.
27. Mosnier LO, Bouma BN, Griffin JH. Platelet Factor 4 upregulates protein C activation relative to TAFI activation. Birmingham, United Kingdom: XIX Congress of The International Society on Thrombosis and Haemostasis; 2003:OC376.
28. Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem. 1997;272:31785-31792.
29. Slungaard A, Key NS. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem. 1994;269:25549-25556.
30. Slungaard A, Fernandez JA, Griffin JH, et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003;102:146-151.
31. Zhang C, Thornton MA, Kowalska MA, et al. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus. Blood. 2001;98:610-617.
32. Tunnacliffe A, Majumdar S, Yan B, Poncz M. Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood. 1992;79:2896-2900.
33. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood. 2003;102:926-933.
34. Broze GJ Jr, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost. 2001;85:747-748.
35. Herzog RW, High KA. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy. Thromb Haemost. 1999;82:540-546.
36. 1 results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A. 2000; 97:9984-9989.
37. Kowalska MA, Ratajczak MZ, Majka M, et al. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood. 2000;96:50-57.
38. Kowalska MA, Ratajczak J, Hoxie J, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol. 1999;104:220-229.
39. Park KS, Rifat S, Eck H, Adachi K, Surrey S, Poncz M. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. Blood. 1990;75:1290-1295.
40. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-280.
41. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation. 1995;91:2188-2194.
42. Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J. 1983;209:455-460.
43. Kaser-Glanzmann R, Jakabova M, Luscher ER Isolation and some properties of the heparin-neutralizing factor (PF4) released from human blood platelets. Experientia. 1972;28:1221-1223.
44. Klener P, Kubisz P. Platelet heparin-neutralizing activity (platelet factor 4). Acta Univ Carol [Med] (Praha). 1978;24:79-86.
45. Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys. 1985;240:446-455.
46. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993;119:874-881.
47. Poon MC, Hurst RE, Rives MS. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density. Thromb Haemost. 1982;47:162-165.
48. Shanberge JN, Quattrociocchi-Longe TM, Martens MH. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. Thromb Res. 1987;46:89-100.
49. Cella G, Myers CJ, Prosdocimi M, Sasahara AA. Human platelet factor 4 and protamine sulphate interaction with glycosaminoglycans in the rabbit. Eur J Clin Invest. 1987;17:548-554.
50. Rabellino EM, Levene RB, Leung LL, Nachman RL. Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med. 1981;154:88-100.
51. Gewirtz AM, Calabretta B, Rucinski B, Niewiarowski S, Xu WY. Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest. 1989;83:1477-1486.
52. Han ZC, Sensebe L, Abgrall JF, Briere J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990;75:1234-1239.
53. Paredes N, Wang A, Berry LR, et al. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. J Biol Chem. 2003;278:23398-23409.
54. Bernabei A, Gikakis N, Maione TE, et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;109:765-771.
55. Shanberge JN, Quattrociocchi-Longe TM. Influence of platelet factor 4 on the neutralization of heparin by protamine. Ann N Y Acad Sci. 1989; 556:354-365.
56. Januzzi JL Jr, Jang IK. Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000;10(Suppl 1):7-11.
57. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev. 2002;16:77-80.
58. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98:2442-2447.